Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A case-control study. by Guler, S.A. et al.
Guler et al. Respir Res          (2021) 22:120  
https://doi.org/10.1186/s12931-021-01727-7
RESEARCH
Performance of a diagnostic algorithm 
for fibrotic hypersensitivity pneumonitis. 
A case–control study
Sabina A. Guler1* , Eva Wohlfarth1,2, Sabina Berezowska3,4, Thomas K. Geiser1, Lukas Ebner5 and 
Manuela Funke‑Chambour1 
Abstract 
Background: The differential diagnosis fibrotic hypersensitivity pneumonitis (HP) versus idiopathic pulmonary 
fibrosis (IPF) is important but challenging. Recent diagnostic guidelines for HP emphasize including multidisciplinary 
discussion (MDD) in the diagnostic process, however MDD is not comprehensively available.
We aimed to establish the diagnostic accuracy and prognostic validity of a previously proposed HP diagnostic algo‑
rithm that foregoes MDD.
Methods: We tested the algorithm in patients with an MDD diagnosis of fibrotic HP or IPF (case control study) and 
determined diagnostic test performances for diagnostic confidences of ≥ 90% and ≥ 70%. Prognostic validity was 
established using Cox proportional hazards models.
Results: Thirty‑one patients with fibrotic HP and 50 IPF patients were included. The algorithm‑derived ≥ 90% confi‑
dence level for HP had high specificity (0.94, 95% confidence interval [CI] 0.83–0.99), but low sensitivity (0.35 [95%CI 
0.19–0.55], J‑index 0.29). Test performance was improved for the ≥ 70% confidence level (J‑index 0.64) with a speci‑
ficity of 0.90 (95%CI 0.78–0.97), and a sensitivity of 0.74 (95%CI 0.55–0.88). MDD fibrotic HP diagnosis was strongly 
associated with lower risk of death (adjusted hazard ratio [HR] 0.10 [0.01–0.92], p = 0.04), whereas the algorithm‑
derived ≥ 70% and ≥ 90% confidence diagnoses were not significantly associated with survival (adjusted HR 0.37 
[0.07–1.80], p = 0.22, and adjusted HR 0.41 [0.05–3.25], p = 0.39, respectively).
Conclusion: The algorithm‑derived ≥ 70% diagnostic confidence had satisfactory test performance for MDD‑HP 
diagnosis, with insufficient sensitivity for ≥ 90% confidence. The lowest risk of death in the MDD‑derived HP diagnosis 
validates the reference standard and suggests that a diagnostic algorithm not including MDD, might not replace the 
latter.
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Background
Interstitial lung diseases (ILD) lead to significant symp-
toms, physical impairment, and early mortality [1, 2]. 
Fibrotic hypersensitivity pneumonitis (HP) is an ILD 
subtype caused by an ongoing or repetitive exposure to 
an inhaled antigen in sensitised and susceptible individu-
als [1]. The identification of patients with HP is crucial, 
particularly to prevent ongoing exposure to the causative 
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antigen. However, in chronic cases where an inciting 
antigen cannot be identified [3], distinguishing fibrotic 
HP from idiopathic pulmonary fibrosis (IPF) is challeng-
ing with considerable diagnostic overlap between these 
fibrotic ILD subtypes [4, 5]. Patients with IPF have a 
worse prognosis than patients with fibrotic HP [6], and 
the immunosuppressive therapy that is frequently used in 
HP can be detrimental for IPF patients [7]. This empha-
sizes the importance of the differential diagnosis fibrotic 
HP versus IPF.
Due to the heterogeneity in clinical presentation 
among patients with fibrotic HP and IPF there is no sin-
gle diagnostic test for accurate discrimination. The recent 
diagnostic guidelines for HP emphasize the importance 
of multidisciplinary discussion (MDD), and include 
MDD in the proposed diagnostic approach [5]. However 
MDDs are time and resource consuming and not widely 
available [8], simpler, accurate tools for HP diagnosis are 
urgently needed. A diagnostic HP algorithm that fore-
goes MDD has been developed by Morisset and group, 
with consensus criteria that were identified by a struc-
tured Delphi approach [9].
The main objective of this case control study was 
to validate the algorithm for the differential diagnosis 
fibrotic HP versus IPF. We aimed to establish the diag-
nostic accuracy of the algorithm, and to determine the 
prognostic validity of the algorithm and MDD derived 
HP diagnoses.
Methods
Study population, setting, and measurements
Patients with fibrotic ILD are prospectively recruited 
within our ongoing cohort study (Swiss Ethics Com-
mittee, Bern, KEK 246/15 PB_2016-01524). For this ret-
rospective case control study, we included consecutive 
patients who were diagnosed with either fibrotic HP 
(cases) or IPF (controls) in our MDD between 03/2013 
and 11/2018. Patients were included if the necessary data 
for a confident MDD diagnosis was available, including 
exposure history, high resolution computed tomogra-
phy (HRCT) chest scans, and cytological or histological 
results if bronchoalveolar lavage (BAL) or lung biopsy 
were performed. All patients were questioned regard-
ing exposure to a potentially inciting antigen using a 
questionnaire customized to our local practice. Antigen 
exposures that were considered relevant for HP included 
mould, hay, agricultural dusts, bird feathers and drop-
pings, and the use of a hot tub, swimming pool, or air 
humidifier.
Aiming to evaluate the diagnostic accuracy and prog-
nostic validity of a fibrotic HP diagnostic algorithm [9], 
we included patients with IPF as a control group, since 
IPF is the most challenging differential diagnosis. We 
defined MDD diagnosis as our reference standard [1, 2, 5, 
8]. As previously described, our MDD meetings include 
experienced chest radiologists, pathologists, and special-
ized ILD physicians [8, 10]. For the purpose of this study, 
a chest radiologist who was blinded for the diagnosis (LE) 
reanalysed the chest CT scans of all IPF and fibrotic HP 
cases.
Patient demographics and baseline characteristics 
were collected from the registry. All measurements 
were accomplished within 3 months of MDD diagnosis. 
Pulmonary function tests were conducted according to 
established protocols [11, 12]. We calculated the Com-
posite Physiologic Index (CPI), which was developed 
to predict radiological extent of fibrosis by aggregating 
forced vital capacity (FVC), forced expiratory volume in 
1 s (FEV1), and diffusing capacity of the lung for carbon 
monoxide (DLCO).[13] Serum IgG against specific anti-
gens were measured in some patients, however results 
were not included in the proposed algorihm [9], and not 
considered for this study.
Algorithm for the diagnosis of fibrotic HP
We applied a slightly adapted version of the HP diagnos-
tic algorithm proposed by Morisset and group [9]. Every 
case was approached in a stepwise manner as outlined in 
the algorithm, starting with stratification by exposure to 
an inciting antigen (Fig. 1). As proposed, a HRCT pattern 
was considered typical for HP if either a combination of 
mosaic attenuation, ground-glass and normal lung, or a 
combination of mosaic attenuation and signs of fibrosis 
were present [9]. Usual interstitial pneumonia (UIP) and 
probable UIP were classified based on the most recent 
diagnostic criteria for IPF [2]. This in slight contrast to 
the Morisset algorithm, which included possible instead 
of probable UIP [14]. We also included other HRCT pat-
terns as a third category, since in our cohort some HRCT 
pattern were neither classified as (probable) UIP nor as 
typical for HP. The threshold for lymphocytosis in BAL 
was set at 40% as suggested [9]. The histopathological fea-
tures for HP included chronic bronchiolocentric inflam-
mation, poorly formed non-necrotizing granulomas, 
giant cells, airway-centred interstitial fibrosis, and the 
absence of an alternative diagnosis [15]. We considered 
provisional diagnosis with high confidence (diagnostic 
confidence 70–89%) and a confident diagnosis (diagnos-
tic confidence ≥ 90%) as diagnostically meaningful for the 
differential diagnosis fibrotic HP versus IPF. Low confi-
dence diagnosis (diagnostic confidence 50–69%) was not 
evaluated for diagnostic test performance [9, 16].
Statistical analysis
Baseline patient data are reported as mean (standard 
deviation) or median (interquartile range).
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Diagnostic test characteristics with 95% confidence 
intervals (95% CI) were calculated for an algorithm 
derived diagnostic confidence ≥ 90% and ≥ 70% with 
an MDD diagnosis of fibrotic HP as reference standard. 
Sensitivity, specificity, positive and negative predic-
tive values (PPV, NPV) were derived from two-by-two 
tables. Youden’s (J) index summarizes sensitivity and 
specificity, and is thus affected by disease prevalence, 
whereas diagnostic accuracy is the proportion of cor-
rectly classified cases among all cases, and not affected 
by disease prevalence. Based on the assumption that 
patients with a “true” diagnosis of fibrotic HP have 
a more favorable prognosis than patients with IPF [6, 
17], we determined the prognostic validity of the MDD 
diagnosis and the algorithm derived diagnosis. Cox 
proportional hazards models were used to determine 
risk of mortality associated with baseline variables and 
fibrotic HP diagnoses (MDD versus algorithm derived). 
Adjusted models included radiological definite or prob-
able UIP pattern, and CPI to account for potential con-
founding by ILD severity. Harrell’s C-statistic was used 
to indicate discrimination of the models. The propor-
tional hazards assumption for all Cox regression mod-
els was tested based on weighted residuals. A two-sided 
p < 0.05 was used to indicate statistical significance. 
Data were analysed using R version 3.6.0 (R Foundation 
for Statistical Computing, Vienna, Austria) [18].
Results
Thirty-one and 50 patients with an MDD diagnosis of 
fibrotic HP or IPF respectively were included in this 
study (Table 1). 78% of the cohort were men with a mean 
Fig. 1 Diagnostic algorithm for fibrotic HP with patients stratified by presence (red) or absence (blue) of an identified antigen exposure. 
*Radiological HP pattern: Combination of mosaic attenuation, ground‑glass and normal lung, or a combination of mosaic attenuation and signs 
of fibrosis. †Radiological definite and probable usual interstitial pneumonia (UIP) based on the 2018 diagnostic criteria for IPF. ‡Pathological HP 
pattern: Chronic bronchiolocentric inflammation, poorly formed non‑necrotizing granulomas, giant cells, airway‑centred interstitial fibrosis, absence 
of an alternative diagnosis. BAL bronchoalveolar lavage, HP hypersensitivity pneumonitis, IPF idiopathic pulmonary fibrosis; UIP usual interstitial 
pneumonia
Table 1 Baseline characteristics by MDD diagnoses
DLCO diffusing capacity of the lung for carbon monoxide, FEV1 forced vital 







Age, years 64.0 (10.7) 68.4 (9.5)
Sex, men 15 (48%) 48 (96%)
Ever smoker 12 (39%) 38 (76%)
Smoked pack years 20 (12.5–50) 30 (20–40)
Body mass index, kg/m2 27.9 (5.4) 27.2 (4.5)
FVC, %‑predicted 73 (23) 65 (17)
FEV1, %‑predicted 74 (18) 70 (17)
FEV1/FVC, % 103 (9) 108 (7)
DLCO, %‑predicted 55 (20) 48 (19)
Composite Physiologic 
Index
42.0 (15.5) 48.5 (13.8)
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(standard deviation) age of 67 (10) years, and a moder-
ately reduced FVC of 68 (19) %-predicted, and a DLCO 
of 51 (20) %-predicted. 40 patients (49%) reported expo-
sures to potentially causative antigens (74% and 34% of 
MDD HP and IPF patients, respectively). A radiological 
probable or definite UIP pattern was present in 29% and 
86% of MDD HP and IPF patients, respectively, with 68% 
of the HP and 8% of the IPF patients showing a radio-
logical pattern compatible with HP. Of the patients with 
MDD diagnosed HP 26 (84%) had BAL available with 
BAL lymphocytosis present in 14 of these cases. BAL was 
available in 21 (42%) of MDD diagnosed IPF cases, with 
lymphocytosis in 3 patients. Surgical lung biopsy was 
available in 22% of IPF and 23% of HP patients.
Diagnostic accuracy
A diagnostic confidence for fibrotic HP of ≥ 90% and a 
diagnostic confidence 70–89% were reached in 14 cases 
each (Fig.  1). The algorithm-derived ≥ 90% confidence 
level had a high specificity (0.94 [95% CI 0.83–0.99]) 
but low sensitivity (0.35 [95% CI 0.19–0.55]) for MDD 
diagnosis of fibrotic HP, with an overall insufficient 
test performance (J-index 0.29 [95% CI 0.03–0.53]). 
The algorithm-derived ≥ 70% confidence level showed 
higher overall test performance (J-index 0.64 [95% CI 
0.34–0.85]) with improved sensitivity (0.74 [95% CI 0.55–
0.88]), positive (0.82 [95% CI 0.63–0.94]), and negative 
predictive values (0.85 [95% CI 0.72–0.93]), with margin-
ally lower specificity (0.90 [95% CI 0.78–0.97]), (Table 2).
Prognostic validity
Over a median time of 16  months (interquartile range 
6–30), 28 patients deceased.
Per one % increase in DLCO patients had a 5% decrease 
in risk of death (hazard ratio [HR] 0.95, 95%CI 0.92–0.98, 
p = 0.007). FVC %-predicted was borderline associated 
with mortality (HR 0.98, 95%CI 0.96–1.00, p = 0.07), 
and CPI was significantly associated with mortality (HR 
1.06, 95%CI 1.01–1.10, p = 0.01). Patients with a definite/
probable radiological UIP pattern had a 5.4 higher risk 
of death (95% CI 1.62–17.8, p = 0.006). Age, sex, smok-
ing status, body mass index, identification of the inciting 
antigen, and availability of surgical lung biopsy were not 
associated with survival.
MDD diagnosis of fibrotic HP was strongly associ-
ated with a lower risk of death on unadjusted analysis 
and with adjustment for potential confounding by dis-
ease severity (CPI) and a radiological UIP pattern (HR 
0.10 [0.01–0.92], p = 0.04). The algorithm derived ≥ 70% 
confidence diagnosis showed a significant association 
with lower risk of death on unadjusted analysis, which 
lost statistical significance on adjusted analysis (HR 0.37 
[0.07–1.80], p = 0.22). The algorithm derived ≥ 90% con-
fidence diagnosis was not significantly associated with 
survival on unadjusted and adjusted analysis (HR 0.41 
[0.05–3.25], p = 0.39), (Table 3, Fig. 2).
Discussion
With this case control study, we validate a previously 
developed diagnostic algorithm for fibrotic HP [9], by 
assessing its diagnostic test performance in a cohort of 
patients with fibrotic HP and a control cohort of patients 
with IPF, using MDD as the reference standard. The algo-
rithm derived diagnostic confidence ≥ 70% demonstrated 
a high specificity, acceptable sensitivity, and a diagnostic 
Table 2 Diagnostic test characteristics for algorithm derived HP 
diagnoses
CI confidence interval, HP hypersensitivity diagnosis, J-index Youden’s index, NPV 
negative predictive value, PPV positive predictive value
Algorithm derived diagnostic 
confidence
 ≥ 90%  ≥ 70%
Sensitivity (95% CI) 0.35 (0.19–0.55) 0.74 (0.55–0.88)
Specificity (95% CI) 0.94 (0.83–0.99) 0.90 (0.78–0.97)
J‑index (95% CI) 0.29 (0.03–0.53) 0.64 (0.34–0.85)
PPV (95% CI) 0.79 (0.49–0.95) 0.82 (0.63–0.94)
NPV (95% CI) 0.70 (0.58–0.81) 0.85 (0.72–0.93)
Diagnostic accuracy 0.71 (0.60–0.81) 0.84 (0.74–0.91)
Table 3 Prognostic validity of MDD and algorithm derived HP diagnoses
C-index Harrell’s C-statistic, HP hypersensitivity pneumonitis, HR hazard ratio, UIP radiological usual interstitial pneumonia pattern
Unadjusted analyses Adjusted for CPI and UIP
HR (95% CI) p-value C-index HR (95% CI) p-value C-index
Multidisciplinary discussion diagnosis for fibrotic HP
 HP 0.06 (0.01–0.45) 0.006 0.68 0.10 (0.01–0.92) 0.04 0.76
Algorithm derived diagnosis for fibrotic HP
  ≥ 90% confidence 0.16 (0.02–1.20) 0.07 0.58 0.41 (0.05–3.25) 0.39 0.72
  ≥ 70% confidence 0.14 (0.03–0.59) 0.007 0.65 0.37 (0.07–1.80) 0.22 0.72
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accuracy of 84%. An algorithm derived diagnostic con-
fidence level ≥ 90% showed poor sensitivity and lower 
diagnostic accuracy (71%) with an expectedly higher 
specificity than the ≥ 70% confidence level. Overall, if 
a confidence level ≥ 70% was considered diagnostic for 
fibrotic HP, the algorithm performed well in our cohort, 
whereas diagnostic performance for the ≥ 90% threshold 
was insufficient.
MDD diagnosis of fibrotic HP showed a stronger asso-
ciation with survival than the algorithm derived diag-
noses on unadjusted analysis, and with adjustment for 
disease severity and UIP pattern, which have been shown 
to impact survival in IPF and fibrotic HP beyond diag-
nosis [6, 17]. This observation strengthens the validity of 
MDD diagnosis as the reference standard in our cohort.
Identification of the inciting antigen is crucial for HP 
diagnosis and management. In patients with an identi-
fied antigen diagnostic confidence for HP is higher [9], 
the danger of IPF misclassification is lower [4], and prog-
nosis is more favorable [3]. However, in less than 50% 
of patients an antigen can be identified [3]. We confirm 
that a systematic exposure assessment is helpful for anti-
gen identification. With a questionnaire tailored to local 
practice we identified an antigen exposure in 74% of HP 
cases, but also in 34% of IPF cases, which underlines the 
low specificity of patient-reported antigen exposure, and 
the need for estimation of potential causality by the clini-
cian [19]. Testing of specific serum IgG levels can confirm 
exposure to the antigen at some point in the patient’s life, 
without prove of causality to the ILD [5].
BAL lymphocytosis is important for HP diagnosis, 
either as a piece of information to the MDD or as a for-
mal diagnostic criterion or integrated in an algorithm. 
However, the optimal BAL lymphocytosis cut-off still 
needs to be determined: A recent meta-analysis dem-
onstrated an optimized sensitivity (71%) and specific-
ity (68%) for a 21% lymphocytosis threshold [20], and a 
threshold of 20% has been proposed to decide if a surgical 
lung biopsy for suspected HP is needed [21]. Conversely, 
most ILD experts indicated that they find a threshold of 
40% to be useful for the diagnosis of chronic HP [9], and 
experts contributing to the new diagnostic guidelines 
indicated that they find a threshold of 30% reasonable [5]. 
Likely different thresholds are valid for different positions 
of BAL in a diagnostic algorithm.
Recent guidelines suggested BAL, transbronchial cry-
obiopsy, and surgical lung biopsy for the diagnosis of 
fibrotic HP with very low confidence [5]. In 2 (6%) of our 
patients with an MDD diagnosis of HP and in 19 (35%) 
of the MDD diagnosed IPF controls, no surgical lung 
biopsy or BAL was performed. In the individual patient, 
the risk–benefit ratio of these invasive procedures is chal-
lenging to estimate. Aside from the diagnostic confidence 
before biopsy (which can be estimated with a diagnostic 
algorithm), the individual procedural risk likely deter-
mines the role of biopsy in the diagnostic algorithm. 
Consequently, a diagnostic HP algorithm might need 
tailoring for patients with advanced disease, important 
comorbidities, and frailty.
The multi-component diagnostic process emphasizes 
the importance of MDDs for diagnostic decision mak-
ing in complex cases. The overlap between fibrotic ILDs 
and the heterogeneity within fibrotic HP and IPF might 
not be sufficiently accounted for by an algorithm in every 
case, and MDD discussion likely provides additional 
granularity for the assessment of complex cases. The 
prognostic validity of chronic HP MDD diagnosis in this 
study further supports this approach. In line, the recent 
diagnostic guidelines for HP confirm the central role of 
MDD in the diagnostic evaluation of patients with pos-
sible HP [5].
Acknowledging the limited availability of resources for 
MDD, a diagnostic algorithm might be valuable to pre-
select typical cases where MDD discussion is less impor-
tant. Future studies might investigate the implementation 
of diagnostic decision trees including the option of MDD 
discussion. Our findings suggest that an algorithm might 
be a valid tool for fibrotic HP diagnosis. The applicabil-
ity of the algorithm might further be improved with 
adaptations according to local practice. Furthermore, 
future integration new diagnostic tools, e.g. blood-based 
Fig. 2 Survival by multidisciplinary discussion a and algorithm 
derived ≥ 70% diagnostic confidence b diagnoses for fibrotic HP 
versus IPF. Survival curves from Cox Proportional Hazard models 
adjusted for Composite Physiological Index and radiological pattern 
of definite or probable UIP pattern. HP hypersensitivity pneumonitis, 
IPF idiopathic pulmonary fibrosis, UIP usual interstitial pneumonia
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biomarkers and genomic classifiers might improve the 
discriminative ability of diagnostic algorithms [22, 23].
Our local single centre study limits generalizability of 
the findings to populations with similar demographics 
and antigen exposure patterns. In our experience IPF is 
the most challenging and impactful differential diagnosis 
of fibrotic HP. However, our results do not apply for other 
differential diagnoses. A recent Japanese study reported 
the chronic HP algorithm to be useful in a heterogene-
ous ILD cohort, with potential avoidance of surgical lung 
biopsy in some of their ILD patients. However, 59% of 
cases were excluded from the algorithm, mainly because 
they did not have radiological features consistent with 
UIP or with HP [24]. By adding the “other radiological 
pattern” category to the algorithm, we ensured that every 
case was captured by the algorithm. Furthermore, preva-
lence of fibrotic ILD subtypes varies between cohorts, 
which can impact on PPV, NPV, and diagnostic accu-
racy. Sensitivity, specificity, and Youden’s index are not 
influenced by disease prevalence. Our adaptations to the 
proposed algorithm were minor, but necessary to include 
all cases and controls in the algorithm. With the applica-
tion of a customized antigen exposure questionnaire and 
detailed interviews, we tried to capture all relevant expo-
sures, however missing exposures are still possible. Incor-
poration bias is an inherent problem to many diagnostic 
test studies in ILD. The diagnostic pieces of the algo-
rithm are also included in MDD discussions, which likely 
inflates the agreement between the two assessments. 
Furthermore, there is no “gold standard” for fibrotic HP 
diagnosis. We tried to account for this by demonstrating 
the prognostic validity of our reference standard.
Conclusion
Current diagnostic guidelines for HP recommend a diag-
nostic approach that includes MDD [5]. In this study, we 
validate a proposed diagnostic algorithm for fibrotic HP 
that foregoes MDD. We demonstrate acceptable test per-
formance of the ≥ 70% diagnostic confidence level com-
pared to the reference standard MDD, and consequently 
endorse the incorporation of algorithms to fibrotic HP 
diagnosis. Due to the low sensitivity and potential danger 
of missing HP cases, we suggest not relying on the cur-
rent algorithm’s ≥ 90% diagnostic confidence level for the 
differential diagnosis HP versus IPF. Algorithms likely 
need to be adapted to regionally distinct exposures, local 
practice, and availability of diagnostic tests, with pro-
spective validation in corresponding cohorts. Further-
more, algorithms might not be sufficiently accurate for 
complex cases and are unlikely to replace MDDs entirely.
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